Literature DB >> 12663337

Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine.

Marjolein Drent1, Suveer Singh, Anton P M Gorgels, David M Hansell, Otto Bekers, Andrew G Nicholson, Robert Jan van Suylen, Roland M du Bois.   

Abstract

Two cases of interstitial pneumonia with cardiac failure developing in patients treated with the new antidepressant venlafaxine are presented. A strong relationship between the development of the patients' illness and the initiation of venlafaxine treatment was identified. The cytochrome P (CYP) 450 system is involved in the metabolism of venlafaxine, suggesting that alterations in the drug metabolic clearance might be, at least in part, responsible for the development of drug-induced damage in these cases. This might occur either as a consequence of a genetic factor or concomitant drug therapy with an inhibitor of the related CYP system. After identifying the causative agent in the first case, withdrawal of the antidepressant together with corticosteroid treatment led to a favorable outcome. In the other case, the multiorgan failure became fatal. These cases highlight a hitherto undescribed association of an adverse lung reaction and heart failure due to venlafaxine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663337     DOI: 10.1164/rccm.200207-739CR

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

Review 2.  Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature.

Authors:  James K Rustad; Theodore A Stern; Kathy A Hebert; Dominique L Musselman
Journal:  Prim Care Companion CNS Disord       Date:  2013-08-15

3.  The development and evaluation of triage algorithms for early discovery of adverse drug interactions.

Authors:  Johanna Strandell; Ola Caster; Johan Hopstadius; I Ralph Edwards; G Niklas Norén
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

4.  Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands.

Authors:  Petal A H M Wijnen; Marjolein Drent; Patty J Nelemans; Petra M J C Kuijpers; Ger H Koek; Cees Neef; Guido R M M Haenen; Otto Bekers
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Duloxetine for the management of fibromyalgia syndrome.

Authors:  Beth A Scholz; Cara L Hammonds; Chad S Boomershine
Journal:  J Pain Res       Date:  2009-07-21       Impact factor: 3.133

6.  Cases of adverse reaction to psychotropic drugs and possible association with pharmacogenetics.

Authors:  Irina Piatkov; Trudi Jones; Mark McLean
Journal:  J Pers Med       Date:  2012-10-01

7.  A case of venlafaxine-induced interstitial lung disease.

Authors:  Serim Oh; Seung-Ick Cha; Hyera Kim; Minjung Kim; Sun Ha Choi; Hyewon Seo; Tae-In Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-08-29

8.  Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine.

Authors:  Pedro Gonçalo Ferreira; Susana Costa; Nuno Dias; António Jorge Ferreira; Fátima Franco
Journal:  J Bras Pneumol       Date:  2014 May-Jun       Impact factor: 2.624

9.  The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study.

Authors:  Ted Rosenberg; Rory Lattimer; Patrick Montgomery; Christian Wiens; Liran Levy
Journal:  Clin Interv Aging       Date:  2017-11-21       Impact factor: 4.458

10.  Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report.

Authors:  Arjan Flora; Daniel Pipoly
Journal:  Drug Saf Case Rep       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.